Update on Infliximab products (Acute sector)
Key messages
• From September 2020, Remsima® is the preferred brand of biosimilar infliximab intravenous (IV) infusion in NHSGGC
• Infliximab is now also available as a subcutaneous (SC) formulation (only Remsima® brand), licensed for a wide range of indications in gastroenterology, rheumatology and dermatology and this has been added to the Adult NHSGGC Formulary (October 2020)
• SC infliximab offers the benefit of self-administration for appropriate patients who have been well controlled on IV infused infliximab
• Note that SC adalimumab (Amgevita®) is the tumour necrosis factor alpha (TNF-α) inhibitor of choice for new patients. Refer to the clinical repository on StaffNet for relevant clinical guidelines.
• Prescribe biosimilars by brand name
Published: 9/11/2020. Medicines Update blogs are correct at the time of publishing